Key result
Suramin improved the electrocardiography profile, decreased the cardiomyopathy index, and reduced myocardial fibrosis, inflammation, and myonecrosis in mdx mice.
Why the study?
Does suramin improve cardiac function and remodeling in the mdx mouse model of Duchenne muscular dystrophy?
Does suramin improve cardiac function and remodeling in the mdx mouse model of Duchenne muscular dystrophy?
Suramin attenuates cardiomyopathy and improves electrocardiographic profiles in a mouse model of Duchenne muscular dystrophy, suggesting potential as an adjunctive therapy.
Hypothesis-generating for suramin in Duchenne cardiomyopathy; human trials needed before any clinical consideration.
INTRODUCTION: The purpose of this study was to determine the effects of suramin, an antifibrotic agent, on cardiac function and remodeling in mdx mice. METHODS: mdx mice (8 months old) received intraperitoneal injections of suramin twice a week for 3 months. Control mdx mice (8 months old) were injected with saline. RESULTS: Suramin improved the electrocardiography profile with the main corrections seen in S- to R-wave ratio, PR interval, and Q amplitude, and a significant decrease in the cardiomyopathy index. Suramin decreased myocardial fibrosis, inflammation, and myonecrosis. CONCLUSIONS: These findings suggest that suramin may be a new adjunctive therapy to help improve cardiomyopathy in DMD.
No takes yet. Share an insight, caveat, or question.
Moreira et al. (2013) studied Duchenne muscular dystrophy (cardiomyopathy). Suramin vs. saline was evaluated on Cardiac function and remodeling (electrocardiography profile, cardiomyopathy index, myocardial fibrosis, inflammation, myonecrosis). Suramin improved the electrocardiography profile, decreased the cardiomyopathy index, and reduced myocardial fibrosis, inflammation, and myonecrosis in mdx mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: